公开(公告)号：EP3427744A1

公开(公告)日：2019-01-16

申请号：EP18159477.1

申请日：2014-03-14

申请人： Bayer Healthcare LLC

发明人： GRITZAN, Uwe ,  KRETSCHMER, Peter ,  LEONG, Lilley ,  PATEL, Chandra

IPC分类号： A61K35/14 ,  C07K1/00 ,  C07K14/00 ,  A61K38/37 ,  C07K14/755

摘要： This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids.

公开(公告)号：EP2461821A1

公开(公告)日：2012-06-13

申请号：EP10805185.5

申请日：2010-08-02

申请人： Bayer HealthCare LLC

发明人： BROOKS, Alan ,  PATEL, Chandra ,  JIANG, Xiaoqiao ,  GRITZAN, Uwe ,  APELER, Heiner ,  WANG, Jun

IPC分类号： A61K38/36

CPC分类号： C12N9/644 ,  A61K38/00 ,  C12Y304/21022

摘要： The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more amino acid substitutions. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor IX polypeptides, for example, to treat patients afflicted with hemophilia B.

公开(公告)号：EP2988758A1

公开(公告)日：2016-03-02

申请号：EP14770221.1

申请日：2014-03-14

申请人： Bayer HealthCare LLC

发明人： GRITZAN, Uwe ,  KRETSCHMER, Peter ,  LEONG, Lilley ,  PATEL, Chandra

IPC分类号： A61K35/14 ,  C07K1/00 ,  C07K14/00 ,  A61K38/37 ,  C07K14/755

CPC分类号： C07K14/755 ,  A61K38/37

摘要： This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids.

公开(公告)号：EP2288622A2

公开(公告)日：2011-03-02

申请号：EP09743241.3

申请日：2009-04-16

申请人： Bayer HealthCare LLC ,  Bayer Schering Pharma Aktiengesellschaft

发明人： BROOKS, Alan ,  MURPHY, John, E. ,  SETO, Marian ,  JIANG, Xiaoqiao ,  PATEL, Chandra ,  GRITZAN, Uwe ,  KIRCHNER, Kornelia ,  HAUPTS, Ulrich

IPC分类号： C07K14/745

CPC分类号： C12N9/644 ,  A61K38/00 ,  C12Y304/21022

摘要： Disclosed are modified Factor IX polypeptides such as Factor IX polypeptides with one or more introduced glycosylation sites. The modified Factor IX polypeptides may exhibit increased in vitro or in vivo stability such as a longer plasma half-life. Also, methods are disclosed of making modified Factor IX polypeptides, and methods of using modified Factor IX polypeptides, for example, to treat patients afflicted with hemophilia B.

公开(公告)号：EP2988758B1

公开(公告)日：2018-04-25

申请号：EP14770221.1

申请日：2014-03-14

申请人： Bayer HealthCare LLC

发明人： GRITZAN, Uwe ,  KRETSCHMER, Peter ,  LEONG, Lilley ,  PATEL, Chandra

IPC分类号： A61K35/14 ,  C07K1/00 ,  C07K14/00 ,  A61K38/37 ,  C07K14/755

CPC分类号： C07K14/755 ,  A61K38/37

摘要： This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids.

公开(公告)号：EP2970500A1

公开(公告)日：2016-01-20

申请号：EP14722465.3

申请日：2014-03-14

申请人： Bayer HealthCare LLC

发明人： JIN, Ye ,  MURPHY, John, E. ,  HERMISTON, Terry ,  MYLES, Timothy ,  DITTMER, Frank ,  STRERATH, Michael ,  GRITZAN, Uwe

IPC分类号： C07K16/38 ,  C12N15/13 ,  A61K39/395 ,  A61P7/04

CPC分类号： C07K16/36 ,  A61K38/4846 ,  A61K45/06 ,  C07K16/18 ,  C07K16/38 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565

摘要： This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin &bgr; complexed with heparin and/or heparin-like structure (AT&bgr;H). These AT&bgr;H binding proteins can block the anti-coagulant activity of AT&bgr; to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.

摘要翻译： 该专利文献涉及针对人类抗凝血酶的抗体，抗原结合抗体片段（Fabs）和其它蛋白质支架; 与肝素和/或肝素样结构复合（AT＆amp; H）。 这些AT＆Bgr H结合蛋白可以阻断AT＆Bgr的抗凝血活性; 诱导凝血。 这些抗体和结合物的治疗用途在本文中描述为淘选和筛选特异性抗体的方法。